By using genetic engineering or recombinant DNA technology, insulin producing genes from human beings have been transferred into E. coli bacteria, which produced insulin called ‘humulin’ for clinical use. This type of synthetic insulin was produced by an American pharmaceutical firm Eli Lily on 5^(th) July 1983.